Peptide Based Cancer Therapeutics Market:Technological Augmentation Drive Growth

Posted by Arslan on June 10th, 2019

Peptide based cancer therapeutics are yet to become widespread, but the initial low numbers certainly do not suggest any pessimism in the global market. With new developments in delivery, stability, modifications, and preclinical success, future growth potentials of such cancer therapeutics continue to intensify.  A slew of new peptides with positive preclinical results are entering into clinical trials that are focused on cancer treatment. Moreover, the application base of peptides is steadily expanding to other therapeutic areas as well. In the near future, the global peptide based cancer therapeutics market is likely to be influenced by the rising prevalence of cancer across the globe.

WHO reveals that cancer is one of the leading causes of death worldwide, which accounted for more than 8 million deaths in 2015. Factor as such are expected to play an important role in boosting the popularity of peptide based cancer therapeutics further. In addition, various complications involved in conventional cancer therapeutics as well as the risk of sever side-effects are prompting medical professionals to utilise peptides in tumor and cancer treatment. Fact.MR’s latest report projects that the global peptide based cancer therapeutics market will surpass a valuation of US$ 11,160 Mn by 2022-end, expanding at an impressive CAGR of 9.2% during the forecast period (2017-2022).

Peptide is a compound that is created by artificial or natural biological chaining of amino acid monomers. In recent years, peptides have emerged as an effective therapeutic agent in treatment of various diseases, including cancer. At present, there are a number of peptide based cancer therapeutics available in the market.  Incessant medical research on peptides has led to development of several peptide based cancer therapeutics that are showing greater results as compared to conventional cancer therapeutics.

North America To Lead The Global Peptide Based Cancer Therapeutics Market

In terms of revenues, North America is expected to dominate the global peptide based cancer therapeutics market in 2017 and beyond. The region’s potency in healthcare and a strong presence of various peptide based cancer therapeutic drug manufacturers is supporting the growth of the market in North America. During the forecast period, the market in the region is expected to surge at a robust CAGR.

View Full Report with Table of Content: https://www.factmr.com/report/179/peptide-based-cancer-therapeutics-market

On the basis of drugs, the bortezomib segment is expected to remain highly attractive throughout the assessment period. The segment currently accounts for around 40% revenue share of the global market. Between 2017 and 2022, the segment is expected to reflect a double-digit CAGR to reach a valuation is excess of US$ 4,725 Mn. It expected to grow at US$ 358.4 Mn annually over the course of the forecast period.

Competition Tracking

Fact.MR’s report has also profiled key companies that are operating in the global peptide based cancer Therapeutic market, which include AstraZeneca PLC, Allergan plc, Pfizer Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Abbott, AbbVie Inc., and Valeant Pharmaceuticals International, Inc.